Amgen Inc v Sanofi (Fed Cir 2021) | McDonnell Boehnen Hulbert & Berghoff LLP jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
To embed, copy and paste the code into your website or blog:
On February 11, 2021, in a unanimous decision, the Federal Circuit affirmed the district court’s holding that Amgen Inc., Amgen Manufacturing, Ltd., and Amgen USA, Inc.’s (collectively, “Amgen’s”) antibody composition claims are invalid for lack of enablement.
Amgen Inc. v. Sanofi, Aventisub LLC, No. 20-1074 (Fed. Cir. 2021).
The patented technology relates to an antibody composition for treating high levels of cholesterol in the blood or hypercholesterolemia.
See id. at 3. A high level of low-density lipoprotein (“LDL”) cholesterol, often called “bad” cholesterol, is associated with heart disease.
Id. LDL receptors (“LDLRs”), present on the surface of cells, bind to LDL cholesterol in the blood and regulate the amount of circulating LDL cholesterol.